Protagonist Therapeutics, Inc - COMMON STOCK (PTGX)

CUSIP: 74366E102

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / COMMON STOCK
Total 13F shares
70,709,835
Total 13F value
$6,175,433,604
Holder snapshot 6 visible 7 signals
Share change
-562,363
Put/Call ratio
5.8%
SEC-reported price per share
$87.34
Number of holders
311
Value change
+$99,663,953
Number of buys
160
Open additional details 1 more signal available
Number of sells
143
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
63,608,245

Security key

74366E102

Report period

Q4 2025

Institutions

311

Top holders

10

PTGX full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Protagonist Therapeutics, Inc SEC filings Protagonist Therapeutics, Inc company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PTGX - Protagonist Therapeutics, Inc - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F 13D/G Lead comparable stake: 14% 13D/G row: BlackRock, Inc. Showing 1-6 of 15 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 14%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 14%
Farallon Capital Partners, L.P. 10%
RTW INVESTMENTS, LP 8.1%
WELLINGTON MANAGEMENT GROUP LLP 5.1%
BIOTECHNOLOGY VALUE FUND L P 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
14%
from 13D/G
$624,723,149
9,404,232 shares
 — 30 Sep 2025
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
13D/G
10%
$545,701,455
6,248,013 shares
 +$25,461,794 31 Dec 2025
RTW INVESTMENTS, LP
13D/G 13F
Company
13D/G 13F
8.1%
$405,989,003
5,059,053 shares
 $0 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP
13D/G 13F
Company
13D/G 13F
5.1%
$254,506,696
3,171,423 shares
 $0 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
13D/G
4.1%
$170,121,650
2,560,916 shares
 -$43,187,804 30 Sep 2025
Deep Track Capital, LP
13D/G 13F
Company
13D/G 13F
2.8%
$113,973,353
1,715,691 shares
 -$101,924,147 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
311
Shares
70,709,835
Rows available
311
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
274
Q4 2025 holders
311
Holder diff
37
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .